No Data
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025
Life Sciences Companies Likely to See Surprisingly Good 1Q Results -- Market Talk
BofA Securities Maintains 10x Genomics(TXG.US) With Hold Rating, Cuts Target Price to $12
BofA Securities Cuts Price Target on 10x Genomics to $12 From $16, Neutral Rating Maintained
Cathie Wood's ARK Investment Buys 191.5K Shares of 10x Genomics Today
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $12